QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing therapies for endocrine, metabolic and cardiovascular diseases.
With four major compounds in their research pipeline, QuatRx's two leading drug candidates --Ophena and fispemifene-- treat endocrine disorders associated with aging. Focused on post-menopausal symptoms in women and testosterone deficiencies in men, the company is aggressively moving forward with promising treatments that could reach markets with annual sales potentials in excess of $1 billion.
QuatRx has also partnered with Newton, PA-based Collagenex to develop and commercialize becocalcidiol, a skin cream used to treat psoriasis, a condition that more than 7.5 million Americans suffer from.
The company has also entered Phase 1 clinical studies on its new cholesterol-lowering compound, QRX-431.
There are 35 employees in Ann Arbor, three of which were added near the end of 2006. Owens anticipates adding a couple more to the staff this year, then holding "at a steady state for a while."
Source: Julia Owens, QuatRx Pharmaceuticals Company